ASTX727 Clinical Trials

10 recruitingDrug
Phase 19Phase 23

Showing 110 of 10 trials

Recruiting
Phase 1

Study to Evaluate the Pharmacokinetics and Safety of Oral Decitabine and Cedazuridine in Cancer Patients With Hepatic Impairment

Acute Myeloid LeukemiaMyelodysplastic Syndromes
Taiho Oncology, Inc.27 enrolled22 locationsNCT04953910
Recruiting
Phase 1

Study to Evaluate the Pharmacokinetics and Safety of Oral Decitabine and Cedazuridine in Cancer Patients With Renal Impairment

Acute Myeloid LeukemiaMyelodysplastic Syndromes
Taiho Oncology, Inc.18 enrolled21 locationsNCT04953897
Recruiting
Phase 1

A Phase Ia/Ib Open-label, Multiple Dose, Study to Determine the Recommended Dose, Evaluate PKs, PDs, Safety, and Activity of Venetoclax in Combination With Oral Decitabine/Cedazuridine (ASTX727) in Pediatric Patients With Relapsed/Refractory Acute Myeloid Leukemia (AML)

Acute Myeloid Leukemia
M.D. Anderson Cancer Center40 enrolled1 locationNCT06191978
Recruiting
Phase 1Phase 2

Active Myeloid Target Compound Combinations in MDS/MPN Overlap Syndromes Overlap Syndromes (ABNL-MARRO)

MDS/MPN
Michael Savona94 enrolled4 locationsNCT04061421
Recruiting
Phase 1

ASTX727 in Recurrent/Progressive Non-enhancing IDH Mutant Gliomas

Neurological Cancer
Massachusetts General Hospital18 enrolled3 locationsNCT03922555
Recruiting
Phase 1Phase 2

A Phase I-II Study Investigating the All-Oral Combination of the Menin Inhibitor SNDX-5613 With Decitabine/Cedazuridine (ASTX727) and Venetoclax in Acute Myeloid Leukemia (SAVE)

Acute Myeloid Leukemia
M.D. Anderson Cancer Center43 enrolled1 locationNCT05360160
Recruiting
Phase 2

A Study of ASTX727 in People With Malignant Peripheral Nerve Sheath Tumors (MPNST)

Malignant Peripheral Nerve Sheath Tumors (MPNST)
Memorial Sloan Kettering Cancer Center25 enrolled7 locationsNCT04872543
Recruiting
Phase 1

Olaparib and ASTX727 in BRCA1/2- and Homologous Recombination Deficient (HRD)-Mutated Tumors

BRCA MutationBRCA1 MutationBRCA2 Mutation+3 more
Pamela Munster18 enrolled1 locationNCT06177171
Recruiting
Phase 1

Lutathera and ASTX727 in Neuroendocrine Tumours

Neuroendocrine Tumors
Imperial College London27 enrolled1 locationNCT05178693
Recruiting
Phase 1

Combination Study of Guadecitabine/ASTX727 and Pembrolizumab

Royal Marsden NHS Foundation Trust60 enrolled2 locationsNCT02998567